Engineered immune cells take on autoimmune diseases in first human test

NCT ID NCT06544330

First seen Nov 05, 2025 · Last updated May 13, 2026 · Updated 21 times

Summary

This early-phase study tests a new treatment that uses a patient's own immune cells, modified to target and calm the overactive immune system causing severe lupus or scleroderma. About 48 adults with these hard-to-treat autoimmune diseases will receive the therapy to see if it is safe and tolerable. The main goal is to check for side effects, while also watching for signs that the disease is getting better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Feinstein Institutes for Medical Research

    Manhasset, New York, 11030, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • HonorHealth Research Institute

    Scottsdale, Arizona, 85258, United States

  • Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210, United States

  • The Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

Conditions

Explore the condition pages connected to this study.